Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

Biotricity, a leading Technology-as-a-Service (TaaS) company in the remote cardiac monitoring sector, has recently filed a patent for its groundbreaking wearable heart monitoring device, Bioheart. Recognized as one of TIME Magazine’s Best Inventions of 2022, Bioheart has been hailed as a “game changer” in the field of personal heart and remote lifestyle monitoring.

The patent application aims to protect Bioheart’s exclusive 3-view dry-contact technology, advanced sensor system, unique design, and compact form factor, which have never been seen before in the consumer market. By securing this patent, Biotricity is reinforcing its commitment to enhancing its Intellectual Property portfolio and solidifying its position as a leader in personal lifestyle and healthcare innovation.

Dr. Waqaas Al-Siddiq, CEO of Biotricity, expressed his pride in the patent filing, stating, “It is with great pride that we announce the filing of our second Biotricity patent in just a month. The Bioheart patent filing reflects our focused commitment to advancing our broader strategy to continuously strengthen our IP, trade secrets, and FDA 510(k) portfolios. This not only helps solidify our leadership in the industry but also ensures that our competitive advantages remain at the forefront of the market.”

Bioheart sets a new industry standard by providing uninterrupted 24/7 heart monitoring, unlike other personal heart rhythm monitors that require manual data collection for brief periods. This innovative device offers more than just data; it provides a comprehensive window into an individual’s heart and overall well-being. With its advanced technology, including three distinct views, seamless data sharing, and constant heart rhythm monitoring, Bioheart empowers users to track, optimize, manage, and gain insights into their heart health.

Biotricity’s unwavering commitment to personal lifestyle and healthcare innovation is evident in the filing of the Bioheart patent. The company consistently pushes the boundaries of technology to redefine the healthcare and lifestyle management landscape. This patent application marks another significant milestone in Biotricity’s journey and further strengthens its existing patent portfolio.

Bioheart is easily accessible for purchase on Amazon or through Biotricity’s website, offering convenience and empowering individuals to take charge of their heart health. To learn more about Biotricity’s cutting-edge solutions in cardiac care, visit their website, where Bioheart is readily available for purchase.

Biotricity, Inc. is revolutionizing the healthcare market by bridging the gap in remote monitoring and chronic care management. The company’s unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions, has gained the trust of doctors and patients alike. Biotricity develops comprehensive remote health monitoring solutions for both the medical and consumer markets.

It’s important to note that any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These statements involve assumptions and describe Biotricity’s future plans, strategies, and expectations. While these forward-looking statements are not meant to predict or guarantee actual results, they reflect Biotricity’s commitment to innovation and its dedication to improving healthcare and lifestyle management.

In conclusion, Biotricity’s patent filing for the Bioheart device highlights the company’s commitment to personal lifestyle and healthcare innovation. With its groundbreaking technology and comprehensive heart monitoring capabilities, Bioheart is set to transform the way individuals manage their heart health. Biotricity’s continuous efforts to strengthen its IP portfolio and push the boundaries of technology solidify its position as a leader in the industry. Embrace the convenience and take charge of your heart health today with Bioheart.

Leave a comment